Skip to main content
SpringerLink
Log in

Cetuximab: 1st-cycle rash a predictor of survival

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Gatzemeier U, von Pawel J, Vynnychenko I, Zatloukal P, De Marinis F, Eberhardt WE, Paz-Ares L, Schumacher KM, Goddemeier T, O’Byrne KJ, Pirker R.First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncology: 17 Dec 2010. Available from: URL: http://dx.doi.org/10.1016/s1470-2045(10)70278-3

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cetuximab: 1st-cycle rash a predictor of survival. React. Wkly. 1339, 2 (2011). https://doi.org/10.2165/00128415-201113390-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201113390-00003

Keywords

Search

Navigation